CONTEXT: Insulin sensitivity is higher in patients with Prader-Willi syndrome (PWS) than in body mass index-matched obese controls (OCs). Factors contributing to the heightened insulin sensitivity of PWS remain obscure. We compared the fasting levels of various hormones, cytokines, lipids, and liver function tests in 14 PWS patients and 14 OCs with those in 14 age- and gender-matched lean children (LC). We hypothesized that metabolic profiles of children with PWS are comparable with those of LC, but different from those of OCs. RESULTS: Leptin levels were comparable in PWS patients and OCs, suggesting comparable degrees of adiposity. Glucose levels were comparable among groups. However, fasting insulin concentrations and homeostasis model assessment insulin resistance index were lower in PWS patients than in OCs (P < 0.05) and similar to LC. Moreover, high-density lipoprotein levels were lower and triglycerides higher in OCs (P < 0.05) but not PWS patients. Total adiponectin, high-molecular-weight (HMW) adiponectin and the HMW to total adiponectin ratio were higher in PWS patients (P < 0.05) than in OCs and similar to LC. High-sensitivity C-reactive protein and IL-6 levels were higher in OCs than in PWS patients or LC (P < 0.05). Nevertheless, PAI-1 levels were elevated in both OC and PWS patients. There were no group differences in glucagon-like peptide-1, macrophage chemoattractant protein-1, TNFα, IL-2, IL-8, IL-10, IL-12p40, IL-18, resistin, total or low-density lipoprotein cholesterol, aspartate aminotransferase, or alanine aminotransferase. CONCLUSIONS: The heightened insulin sensitivity of PWS patients relative to OCs is associated with higher levels of adiponectin and lower levels of high-sensitivity C-reactive protein and IL-6. Future studies will determine whether PWS children are protected from obesity comorbidities such as type 2 diabetes, hyperlipidemia, and nonalcoholic fatty liver disease.
CONTEXT: Insulin sensitivity is higher in patients with Prader-Willi syndrome (PWS) than in body mass index-matched obese controls (OCs). Factors contributing to the heightened insulin sensitivity of PWS remain obscure. We compared the fasting levels of various hormones, cytokines, lipids, and liver function tests in 14 PWSpatients and 14 OCs with those in 14 age- and gender-matched lean children (LC). We hypothesized that metabolic profiles of children with PWS are comparable with those of LC, but different from those of OCs. RESULTS: Leptin levels were comparable in PWSpatients and OCs, suggesting comparable degrees of adiposity. Glucose levels were comparable among groups. However, fasting insulin concentrations and homeostasis model assessment insulin resistance index were lower in PWSpatients than in OCs (P < 0.05) and similar to LC. Moreover, high-density lipoprotein levels were lower and triglycerides higher in OCs (P < 0.05) but not PWSpatients. Total adiponectin, high-molecular-weight (HMW) adiponectin and the HMW to total adiponectin ratio were higher in PWSpatients (P < 0.05) than in OCs and similar to LC. High-sensitivity C-reactive protein and IL-6 levels were higher in OCs than in PWSpatients or LC (P < 0.05). Nevertheless, PAI-1 levels were elevated in both OC and PWSpatients. There were no group differences in glucagon-like peptide-1, macrophage chemoattractant protein-1, TNFα, IL-2, IL-8, IL-10, IL-12p40, IL-18, resistin, total or low-density lipoprotein cholesterol, aspartate aminotransferase, or alanine aminotransferase. CONCLUSIONS: The heightened insulin sensitivity of PWSpatients relative to OCs is associated with higher levels of adiponectin and lower levels of high-sensitivity C-reactive protein and IL-6. Future studies will determine whether PWSchildren are protected from obesity comorbidities such as type 2 diabetes, hyperlipidemia, and nonalcoholic fatty liver disease.
Authors: P Eriksson; V Van Harmelen; J Hoffstedt; P Lundquist; H Vidal; V Stemme; A Hamsten; P Arner; S Reynisdottir Journal: Thromb Haemost Date: 2000-04 Impact factor: 5.249
Authors: David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Riitta Salonen; Rainer Rauramaa; Jukka T Salonen Journal: Eur J Endocrinol Date: 2003-12 Impact factor: 6.664
Authors: A P Goldstone; E L Thomas; A E Brynes; J D Bell; G Frost; N Saeed; J V Hajnal; J K Howard; A Holland; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: T Cadoudal; M Buléon; C Sengenès; G Diene; F Desneulin; C Molinas; S Eddiry; F Conte-Auriol; D Daviaud; P G P Martin; A Bouloumié; J-P Salles; M Tauber; P Valet Journal: Int J Obes (Lond) Date: 2014-01-10 Impact factor: 5.095
Authors: Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan Journal: CNS Drugs Date: 2012-04-01 Impact factor: 5.749
Authors: Krystal A Irizarry; Diana R Mager; Lucila Triador; Michael J Muehlbauer; Andrea M Haqq; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2019-01-31 Impact factor: 3.478
Authors: Krystal A Irizarry; James Bain; Merlin G Butler; Olga Ilkayeva; Michael Muehlbauer; Andrea M Haqq; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2015-04-01 Impact factor: 3.478
Authors: Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler Journal: Diabetes Obes Metab Date: 2017-07-13 Impact factor: 6.577